• Something wrong with this record ?

The effect of enzyme therapy on skin symptoms and immune responses in patients with dermatitis herpetiformis

Agnieszka Zebrowska, Hugh J. Cornell, Finlay A. Macrae, Anna Sysa-Jedrzejowska, Elzbieta Waszczykowska, Teodor Stelmasiak

. 2014 ; 2 (2) : 58-63.

Language English Country United States

Document type Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15025284

The aetiology of coeliac disease (CD) has many similarities to that of dermatitis herpetiformis (DH), except that DH lesions are mainly manifested in the skin. Mucosal enzyme deficiency plays an important part in CD pathology. Clinical studies indicated that the gluten exposure in CD could be partly corrected by the use of enzyme supplementation. Objective: Enzyme therapy, using enterically coated tablets containing caricain, was investigated as a means of protecting patients with DH against wheat gluten. Methods: A randomized, placebo-controlled clinical trial was carried out on 20 DH patients in clinical remission. The patients were divided into two groups of 10, one group given a placebo daily and the other the enzyme – containing tablets. Both groups were challenged with 6g of gluten daily in a double-blind trial. Symptoms and signs of skin involvement were recorded and graded at the start of the trial, after 7 days and after 14 days. Blood was also taken at the start and after 14 days and assayed for IgA EMA and anti-gliadin antibodies. Results: After 7 days the major features associated with DH were more severe and more common with the placebo compared with enzyme therapy. Before 14 days, seven patients in total, six on placebo, had to withdraw from the trial because of the effects of the gluten challenge whilst 2 patients on therapy developed blisters, erythema and itching. Serological tests indicated that IgA EmA antibodies and anti-gliadin antibodies after 14 days were not affected significantly, but indicated that abnormally high antibodies titers of both types were present in 8 patients at the start of the trial, suggesting the need for enzyme therapy in addition to the normal gluten-free diet for patient well-being. Conclusions: This study supports the use of enzyme supplementation as a safeguard for patients with DH on a nominal gluten-free diet.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc15025284
003      
CZ-PrNML
005      
20151116115522.0
007      
ta
008      
150724s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.12691/ijcd-2-2-7 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zebrowska, Agnieszka $u Department of Dermatology and Venereology, Lodz Medical University, Lodz, Poland
245    14
$a The effect of enzyme therapy on skin symptoms and immune responses in patients with dermatitis herpetiformis / $c Agnieszka Zebrowska, Hugh J. Cornell, Finlay A. Macrae, Anna Sysa-Jedrzejowska, Elzbieta Waszczykowska, Teodor Stelmasiak
504    __
$a Literatura
520    9_
$a The aetiology of coeliac disease (CD) has many similarities to that of dermatitis herpetiformis (DH), except that DH lesions are mainly manifested in the skin. Mucosal enzyme deficiency plays an important part in CD pathology. Clinical studies indicated that the gluten exposure in CD could be partly corrected by the use of enzyme supplementation. Objective: Enzyme therapy, using enterically coated tablets containing caricain, was investigated as a means of protecting patients with DH against wheat gluten. Methods: A randomized, placebo-controlled clinical trial was carried out on 20 DH patients in clinical remission. The patients were divided into two groups of 10, one group given a placebo daily and the other the enzyme – containing tablets. Both groups were challenged with 6g of gluten daily in a double-blind trial. Symptoms and signs of skin involvement were recorded and graded at the start of the trial, after 7 days and after 14 days. Blood was also taken at the start and after 14 days and assayed for IgA EMA and anti-gliadin antibodies. Results: After 7 days the major features associated with DH were more severe and more common with the placebo compared with enzyme therapy. Before 14 days, seven patients in total, six on placebo, had to withdraw from the trial because of the effects of the gluten challenge whilst 2 patients on therapy developed blisters, erythema and itching. Serological tests indicated that IgA EmA antibodies and anti-gliadin antibodies after 14 days were not affected significantly, but indicated that abnormally high antibodies titers of both types were present in 8 patients at the start of the trial, suggesting the need for enzyme therapy in addition to the normal gluten-free diet for patient well-being. Conclusions: This study supports the use of enzyme supplementation as a safeguard for patients with DH on a nominal gluten-free diet.
650    12
$a dermatitis herpetiformis $x diagnóza $x dietoterapie $x imunologie $x krev $x patofyziologie $7 D003874
650    _2
$a celiakie $7 D002446
650    12
$a kožní manifestace $7 D012877
650    12
$a gluteny $x aplikace a dávkování $x diagnostické užití $x farmakologie $x imunologie $x škodlivé účinky $x účinky léků $7 D005983
650    12
$a enzymoterapie $7 D057487
650    _2
$a tablety $7 D013607
650    12
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a výsledek terapie $7 D016896
650    _2
$a ochranné faktory $7 D065840
650    _2
$a histologické techniky $x metody $x využití $7 D006652
650    _2
$a imunologické testy $x metody $x využití $7 D007159
650    _2
$a interpretace statistických dat $7 D003627
650    _2
$a věkové faktory $7 D000367
650    _2
$a sérologie $7 D012699
650    _2
$a gastrointestinální trakt $x patofyziologie $7 D041981
650    _2
$a potravní doplňky $7 D019587
650    _2
$a enzymy $x aplikace a dávkování $x farmakologie $x imunologie $7 D004798
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
651    _2
$a Austrálie $7 D001315
651    _2
$a Polsko $7 D011044
653    00
$a caricain
653    00
$a endomysiální protilátky IgA
653    00
$a protilátky antigliadinu
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cornell, Hugh J. $u School of Applied Science, RMIT University, Melbourne, Victoria, Australia
700    1_
$a Macrae, Finlay A. $u Department of Colorectal Medicine and Genetics, and University of Melbourne Department Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia
700    1_
$a Jedrzejowska, Anna Sysa $u Department of Dermatology and Venereology, Lodz Medical University, Lodz, Poland
700    1_
$a Waszczykowska, Elzbieta $u Department of Dermatology and Venereology, Lodz Medical University, Lodz, Poland
700    1_
$a Stelmasiak, Teodor $u Glutagen Pty Ltd, Maribyrnong, Victoria, Australia
773    0_
$t International journal of celiac disease $x 2334-3427 $g Roč. 2, č. 2 (2014), s. 58-63 $w MED00186448
856    41
$u http://www.sciepub.com/journal/index.aspx?id=ijcd $y domovská stránka časopisu
910    __
$a ABA008 $b B 2748 $c 280 $y 4 $z 0
990    __
$a 20150723102837 $b ABA008
991    __
$a 20151116115545 $b ABA008
999    __
$a ok $b bmc $g 1085509 $s 908290
BAS    __
$a 3
BMC    __
$a 2014 $b 2 $c 2 $d 58-63 $i 2334-3427 $m International journal of celiac disease $x MED00186448
LZP    __
$c NLK185 $d 20151116 $a NLK 2015-19/mk

Find record

Citation metrics

Archiving options